• 1

    World Health Organization, 1979. Synopsis of the world’s malaria situation. Wkly Epidemiol 56 :145–149.

  • 2

    Chai JY, 1999. Re-emerging Plasmodium vivax malaria in the Republic of Korea. Korean J Parasitol 37 :129–143.

  • 3

    Ree HI, 2000. Unstable vivax malaria in Korea. Korean J Parasitol 38 :119–138.

  • 4

    Frieghner BH, Park HI, Novaskoski WL, Kelsey LL, Strickmann D, 1998. Reemergence of P. vivax in the Republic of Korea. Emerg Infect Dis 4 :295–297.

    • Search Google Scholar
    • Export Citation
  • 5

    Han ET, Lee DH, Park KD, Seok WS, Kim YS, Tsuboi T, Shin EH, Chai JY, 2006. Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol 44 :285–294.

    • Search Google Scholar
    • Export Citation
  • 6

    Hankey DD, Jones R Jr, Coatney GR, Alving AS, Coker WG, Garrison PL, Donovan WN, 1953. Korean vivax malaria. I. Natural history and response to chloroquine. Am J Trop Med Hyg 2 :958–969.

    • Search Google Scholar
    • Export Citation
  • 7

    Garnham PC, Bray RS, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Sergiev PG, Tiburskaja NA, Shute PG, Maryon M, 1975. A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Bull World Health Organ 52 :21–32.

    • Search Google Scholar
    • Export Citation
  • 8

    Shute PG, Lupascu G, Branzei P, Maryon M, Constantinescu P, Bruce-Chwatt LJ, Draper CC, Killick-Kendrick R, Garnham PC, 1977. A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg 70 :474–481.

    • Search Google Scholar
    • Export Citation
  • 9

    Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ, 1991. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 85 :424–429.

    • Search Google Scholar
    • Export Citation
  • 10

    Nosten F, McGready R, Simpson J, Thwai KL, Balkan S, Cho L, Hkirijareon L, Looareesuwan S, White NJ, 1999. Effects of Plasmodium vivax malaria in pregnanacy. Lancet 14 :546–549.

    • Search Google Scholar
    • Export Citation
  • 11

    Schuurkamp G, Spicer PE, Kereu RK, Bulungol PK, 1992. Chloroquine resistant P. vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 86 :121–122.

    • Search Google Scholar
    • Export Citation
  • 12

    Marfurt J, Müeller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B, 2007. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 77 :947–954.

    • Search Google Scholar
    • Export Citation
  • 13

    Baird JK, Basri, Purnomo, Bang MJ, Subbianto B, Patchen LC, Hoffmann SL, 1991. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 44 :547–555.

    • Search Google Scholar
    • Export Citation
  • 14

    Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK, 2003. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 68 :416–420.

    • Search Google Scholar
    • Export Citation
  • 15

    Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN, 2008. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 17 :128.

    • Search Google Scholar
    • Export Citation
  • 16

    Phillips EJ, Keystone JS, Kain KC, 1996. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis 23 :1171–1173.

    • Search Google Scholar
    • Export Citation
  • 17

    Soto J, Toledo J, Gutierrz P, Luzz M, Linas N, Cedeno N, Dunne M, Berman J, 2001. Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg 65 :90–93.

    • Search Google Scholar
    • Export Citation
  • 18

    Dua VK, Kar PK, Sharma VP, 1996. Chloroquine resistant P. vivax malaria in India. Trop Med Int Health 1 :816–819.

  • 19

    Than M, Kyaw MP, Soe AY, Gyi KK, Sabai M, Oo M, 1995. Development of resistance to chloroquine by P. vivax in Myanmar. Trans R Soc Trop Med Hyg 89 :307–308.

    • Search Google Scholar
    • Export Citation
  • 20

    Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M, Zaw T, Annerberg A, de Radiguès X, Nosten F, 2008. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health 13 :91–98.

    • Search Google Scholar
    • Export Citation
  • 21

    Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN, 2007. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and postreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 44 :1067–1074.

    • Search Google Scholar
    • Export Citation
  • 22

    Chotivanich K, Silamut K, Udomsangpetch R, Stepnewski K, Pukrittayakamee S, Looareesuwan S, White NJ, 2001. Ex-vivo short-term culture and developmental assessment of Plasmodium vivax. Trans R Soc Trop Med Hyg 95 :677–680.

    • Search Google Scholar
    • Export Citation
  • 23

    Simpson J, Silamut K, Chotivanich K, Pukrittayakamee S, White NJ, 1999. Red cell selectivity in malaria: a study of multiple infected erythrocytes. Trans R Soc Trop Med Hyg 93 :165–168.

    • Search Google Scholar
    • Export Citation
  • 24

    Kimura M, Kaneko O, Qing L, Mian Z., Kawamoto F, Wataya Y, Otani S, Yamaguchi Y, Tanabe K, 1997. Identification of the four species of human PCR diagnosis for four human malaria parasites. The Toyota Foundation Mini-Symposium on Malaria. Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

  • 25

    Chotivanich K, Udomsangpetch R, Chierakul W, Newton P, Ruangweerayuth R, Pukrittayakamee, Looaresuwan S, White NJ, 2004. In vitro efficacy of antimalarial drugs againt P. vivax on the western border of Thailand. Am J Trop Med Hyg 70 :395–397.

    • Search Google Scholar
    • Export Citation
  • 26

    Yeom JS, Ryu SH, Oh S, Lee WJ, Kim TS, Kim KH, Kim YA, Ahn SY, Cha JE, Park JW, 2005. Status of Plasmodium vivax malaria in the Republic of Korea during 2001–2003. Am J Trop Med Hyg 73 :604–608.

    • Search Google Scholar
    • Export Citation
  • 27

    Alving AS, Hankey DD, Castney GR, Jones R Jr, Coker WG, Garrison PL, Donovan WN, 1953. Korean vivax malaria II. Curative treatment with pamaquine and primaquine. Am J Trop Med Hyg 2 :970–976.

    • Search Google Scholar
    • Export Citation
  • 28

    Kim C, Shin DC, Yong TS, Oh DK, Kim RK, Park K, Suh IL, 2006. Chemoprophylaxis and the epidemiological characteristics of re-emergent P. vivax malaria in the Republic of Korea. Bull World Health Organ 84 :827–834.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Antimalarial Drug Susceptibility of Plasmodium vivax in the Republic of Korea

View More View Less
  • 1 Faculty of Tropical Medicine, and Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand; Department of Entomology, Armed Forces Research Institute of Medical Science, Bangkok, Thailand; Department of Entomology, Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea; Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Republic of Korea; Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
Restricted access

The antimalarial susceptibility of ring stage (> 80%) Plasmodium vivax from the Republic of Korea, where long incubation–period strains are prevalent, was evaluated using the schizont maturation inhibition technique. During 2005–2007, susceptibility to seven antimalarial drugs was evaluated with 24 fresh isolates. The geometric mean (95% confidence interval) 50% inhibition concentration (IC50) were quinine 60 (54–75) ng/mL, chloroquine 39 (22–282) ng/mL, piperaquine 27 (17–58) ng/mL, mefloquine 39 (35–67) ng/mL, pyrimethamine 138 (89–280) ng/mL, artesunate 0.6 (0.5–0.8) ng/mL, and primaquine 122 (98–232) ng/mL. Positive correlations were found between quinine and mefloquine (r = 0.6, P = 0.004), piperaquine and chloroquine (r = 0.6, P = 0.008), and piperaquine and primaquine IC50 values (r = 0.5, P = 0.01). Compared with P. vivax in Thailand, P. vivax in the Republic of Korea was more sensitive to quinine and mefloquine, but equally sensitive to chloroquine and artesunate.

Save